PhD Scientific Days 2025

Theoretical and Translational Medicine III.

Investigating the effect of metabolic syndrome on the exocrine pancreas after acute pancreatitis

Előadó neve

Dr. Lipp Mónika

Neptun code

CPSO7K

Előadó munkahelye

Semmelweis University

Előadó telefonszáma

+36305027653

Előadó e-mail címe

lipp.monika@gmail.com

Az előadás címe

Investigating the effect of metabolic syndrome on the exocrine pancreas after acute pancreatitis

Szerző(k) neve és munkahelye

Mónika Lipp¹, Andrea Szentesi², Zsolt Abonyi-Tóth², Vivien Vass³, Katalin Márta¹, Ferenc Izbéki⁴, László Gajdán⁴, Bálint Erőss¹, Péter Hegyi¹, Alexandra Mikó²

1: Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary
2: Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
3: Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary
4: Szent György Teaching Hospital of Fejér County, Székesfehérvár, Hungary

Bemutatás módja

Szóbeli

Szekció

Theoretical and Translational Medicine III.

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Aims
Recent data highlight a significant risk of mortality following acute pancreatitis (AP), with a one-year mortality rate of 5.5%, emphasizing the need for long-term follow-up. Multiple metabolic syndrome factors are associated with worse outcomes. The GOULASH PLUS study (ISRCTN63396106), a longitudinal, observational multicentre trial, aims to evaluate the role of metabolic syndrome in pancreatic disease progression. The study has reached 50% of its planned enrolment. This interim analysis examines the impact of metabolic factors on disease progression.

Method
Data from 357 patients were analyzed for metabolic syndrome factors: obesity, hypertension, hypertriglyceridemia, hypercholesterolemia, and diabetes. Patients were categorized into four groups based on exocrine pancreatic morphology: (1) single AP episode, (2) recurrent AP (RAP, ≥2 episodes), (3) early chronic pancreatitis (ECP, ≥3 episodes or imaging signs), and (4) chronic pancreatitis (CP). Imaging included abdominal ultrasound in years 1 and 3; EUS or MRCP in years 2 and 4.

Results
Among 194 obese AP patients, 27 (13.9%) progressed to RAP, ECP, or CP by year 4. In contrast, 20 of 43 non-obese AP patients (46.5%) showed progression. Of 160 hypertensive AP patients, 29 (18.1%) progressed versus 9 of 84 non-hypertensives (10.7%). Among 48 with abnormal triglycerides, 11 (22.9%) progressed, versus 27 of 194 with normal levels (13.9%). Of 68 with hypercholesterolemia, 12 (17.6%) progressed, compared to 26 of 170 with normal cholesterol (15.3%). Regarding glucose metabolism, 35 of 144 with prediabetes/diabetes (24.3%) progressed versus 54 of 208 with normal glucose (25.9%). Not all patients completed year-four follow-up.

Conclusion
By year four, metabolic factors affected progression to RAP, ECP, or CP. Surprisingly, non-obese AP patients had higher progression rates, potentially due to early cholecystectomy in obese patients. Hypertension, elevated triglycerides, and cholesterol modestly increased progression risk. Glucose abnormalities had no significant impact.

University

Semmelweis University

Supervisor

Prof. Dr. Hegyi Péter, Dr. Mikó Alexandra

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

jóváhagyta

Előadó

3671

Start

16:00

End

16:15